Table 1.
Demographic characteristics of patients.
| Variable |
No Insulin Resistance (TyG <8.4) (N = 262) |
Insulin resistance (TyG ≥8.4) (N = 652) |
p-value |
|---|---|---|---|
| Age (years) | 69.8 ± 13.0 | 68.8 ± 11.9 | 0.2941 |
| Age groups (years) | 0.5287 | ||
| 20–39 years | 2.3% (6/262) | 1.2% (8/652) | |
| 40–49 years | 3.1% (8/262) | 3.5% (23/652) | |
| 50–59 years | 16.0% (42/262) | 17.9% (117/652) | |
| 60–69 years | 21.4% (56/262) | 25.8% (168/652) | |
| 70–79 years | 33.2% (87/262) | 31.8% (207/652) | |
| 80–89 years | 21.4% (56/262) | 17.5% (114/652) | |
| ≥ 90 years | 2.7% (7/262) | 2.3% (15/652) | |
| Female sex; n (%) | 36.6% (96/262) | 36.2% (236/652) | 0.8994 |
| Alcoholism; n/total N (%) | 25/262 (9.5%) | 61/652 (9.4%) | 0.9305 |
| Mean NIHSS on arrival | 14.2 ± 6.6 | 13.6 ± 7.4 | 0.2809 |
| Stroke Severity at baseline | 0.1678 | ||
| Mild (NIHSS of 4–8) | 72/262 (27.5%) | 178/652 (27.3%) | |
| Moderate (NIHSS of 9–15) | 80/262 (30.5%) | 238/652 (36.5%) | |
| High (NIHSS of ≥ 16) | 110/262 (42.0%) | 236/652 (36.2%) | |
| Alteplase dose (mg/kg) | 0.78 ± 0.14 | 0.80 ± 0.14 | 0.0747 |
| Groups of Alteplase dosage | 0.9898 | ||
| Standard dose (0.9 mg/kg) | 67/262 (25.6%) | 167/652 (25.6%) | |
| Low dose (<0.9 mg/kg) | 195/262 (74.4%) | 485/652 (74.4%) | |
| Blood pressure on arrival | |||
| Systolic BP (mmHg) | 154.1 ± 29.1 | 161.6 ± 29.6 | 0.0011* |
| Diastolic BP (mmHg) | 87.6 ± 18.3 | 91.4 ± 19.7 | 0.0078* |
| Time to treatment (min) | 131.3 ± 46.7 | 130.6 ± 46.4 | 0.8441 |
| Medical history | |||
| Hypertension | 168/262 (64.1%) | 508/652 (77.9%) | <0.0001* |
| Diabetes mellitus | 37/262 (14.1%) | 279/652 (42.8%) | <0.0001* |
| Coronary artery disease | 35/262 (13.4%) | 105/652 (16.1%) | 0.2973 |
| Atrial fibrillations | 131/208 (63.0%) | 268/501 (53.5%) | 0.0204* |
| Antithrombotic use | |||
| Aspirin | 33/148 (22.3%) | 85/365 (23.3%) | 0.8092 |
| Clopidogrel | 4/148 (2.7%) | 18/365 (4.9%) | 0.2589 |
| Ticlopidine | 1/148 (0.7%) | 1/365 (0.3%) | 0.4942 |
| Warfarin | 8/148 (1.6%) | 12/365 (3.3%) | 0.3133 |
| Metabolism markers | |||
| Fasting glucose | 103.5 ± 25.8 | 153.3 ± 115.2 | <0.0001* |
| Lipids (mg/dL) | |||
| Total cholesterol | 160.9 ± 39.3 | 191.7 ± 46.9 | <0.0001* |
| LDL-C | 95.2 ± 33.4 | 115.7 ± 42.5 | <0.0001* |
| HDL-C | 49.6 ± 20.9 | 48.1 ± 25.4 | 0.3985 |
| TG | 64.7 ± 19.0 | 147.4 ± 82.9 | <0.0001* |
BP, blood pressure; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; NIHSS, National Institutes of Health Stroke Scale; TG, triglyceride; TyG, triglyceride-glucose index.
Continuous variables are expressed as the mean ± SD.
*
Statistically significant at p < 0.0.